CIK 0001604464 · Non-accelerated filer<br>Smaller reporting company
Atara Biotherapeutics, Inc.
Sign in to watch- Ticker
- ATRA
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 460920988
- Phone
- 805-623-4211
- Business address
- 1280 RANCHO CONEJO BLVD, THOUSAND OAKS, CA, 91320
- Open-market buys, last 90 days
- $999,994
- in 1 filing
- Open-market sales, last 90 days
- $40,883
- in 1 filing
Net +$959,111. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-05-17 | Dupont Jakob EVP, Head of R&D | Sale | −3,873 | $5.32 | $21K | 163,006 |
| 2022-05-17 | Touchon Pascal President and CEO | Sale | −13,913 | $5.32 | $74K | 486,313 |
| 2022-03-01 | Koppikar Utpal Chief Financial Officer | Grant or award | +61,235 | 216,937 | ||
| 2022-03-01 | Koppikar Utpal Chief Financial Officer | Sale | −2,272 | $9.86 | $22K | 214,665 |
| 2022-03-01 | Koppikar Utpal Chief Financial Officer | Sale | −1,491 | $9.86 | $15K | 213,174 |
| 2022-03-01 | Koppikar Utpal Chief Financial Officer | Grant or award · Employee Stock Option (Right to Buy) | +115,107 | 115,107 | ||
| 2022-03-01 | Yarema Kristin Chief Commercial Officer | Grant or award | +45,533 | 171,415 | ||
| 2022-03-01 | Yarema Kristin Chief Commercial Officer | Grant or award · Employee Stock Option (Right to Buy) | +85,592 | 85,592 | ||
| 2022-03-01 | Dupont Jakob EVP, Head of R&D | Grant or award | +78,506 | 169,100 | ||
| 2022-03-01 | Dupont Jakob EVP, Head of R&D | Sale | −2,221 | $9.86 | $22K | 166,879 |
| 2022-03-01 | Dupont Jakob EVP, Head of R&D | Grant or award · Employee Stock Option (Right to Buy) | +147,573 | 147,573 | ||
| 2022-03-01 | Touchon Pascal President and CEO | Grant or award | +180,565 | 509,054 | ||
| 2022-03-01 | Touchon Pascal President and CEO | Sale | −8,828 | $9.86 | $87K | 500,226 |
| 2022-03-01 | Touchon Pascal President and CEO | Grant or award · Employee Stock Option (Right to Buy) | +339,419 | 339,419 | ||
| 2022-03-01 | Murugan Amar SVP, GC & Secretary | Grant or award | +51,814 | 139,535 | ||
| 2022-03-01 | Murugan Amar SVP, GC & Secretary | Sale | −1,465 | $9.86 | $14K | 138,070 |
| 2022-03-01 | Murugan Amar SVP, GC & Secretary | Sale | −1,112 | $9.86 | $11K | 136,958 |
| 2022-03-01 | Murugan Amar SVP, GC & Secretary | Grant or award · Employee Stock Option (Right to Buy) | +97,398 | 97,398 | ||
| 2022-02-10 | Dupont Jakob EVP, Head of R&D | Option exercise | +5,000 | $9.58 | $48K | 95,594 |
| 2022-02-10 | Dupont Jakob EVP, Head of R&D | Sale | −5,000 | $16.00 | $80K | 90,594 |
Page 11 of 17 · 334 trades